Quality of Life and Cognitive Functioning in Patients With Glial Tumors
2 other identifiers
interventional
90
1 country
1
Brief Summary
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 21, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedFirst Submitted
Initial submission to the registry
February 6, 2026
CompletedFirst Posted
Study publicly available on registry
February 18, 2026
CompletedFebruary 18, 2026
February 1, 2026
6.3 years
February 6, 2026
February 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20)
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment.
Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Secondary Outcomes (1)
Change in Cognitive Function Test Performance (Neuropsychological Test Battery)
Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Study Arms (1)
Glioma Patients
OTHERPatients with glial tumors assessed for quality of life and cognitive functioning as prognostic factors.
Interventions
Assessment of cognitive functioning and quality of life in patients with glial tumors to evaluate their prognostic value and impact on survival outcomes.
Eligibility Criteria
You may qualify if:
- Adult participants (≥18 years)
- Patients with histologically confirmed glial tumour
- Ability to understand the study procedures and provide written informed consent
- Ability to complete quality of life questionnaires and cognitive testing
You may not qualify if:
- Age \<18 years
- Inability to provide informed consent
- Severe cognitive impairment or clinical condition preventing completion of questionnaires and cognitive testing
- Insufficient language proficiency to complete the questionnaires and neuropsychological testing
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2026
First Posted
February 18, 2026
Study Start
September 21, 2018
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
February 18, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share